Results 211 to 220 of about 14,830 (306)

PANI/PTA/Fe3O4 Nanocomposite Coated on Stainless‐Steel Towards Efficient Solid‐Phase Microextraction of Tetracycline From Human Urine Samples Prior to HPLC–DAD Analysis

open access: yesAnalytical Science Advances, Volume 7, Issue 1, June 2026.
ABSTRACT Tetracycline (TC) is a commonly prescribed broad‐spectrum antibiotic, and its widespread use together with its persistence in biological matrices, particularly urine, has raised serious concerns related to clinical safety, public health and the emergence of antimicrobial resistance, underscoring the need for its accurate and sensitive ...
Sanaz Naghinejad Orang   +2 more
wiley   +1 more source

Hepatocyte growth factor/c‐Met signaling axis in human diseases: Mechanistic insights and therapeutic potential

open access: yesJournal of Cell Communication and Signaling, Volume 20, Issue 2, June 2026.
Figure 1 visually summarizes the core biological functions and therapeutic potential of the HGF/c‐Met signaling axis. Abstract Hepatocyte growth factor (HGF) is a multifunctional cytokine that activates the tyrosine kinase activity of its specific receptor, c‐Met (mesenchymal–epithelial transition factor).
Hongqin Sun   +7 more
wiley   +1 more source

OXALATES [PDF]

open access: yesChemical & Engineering News Archive, 1946
openaire   +1 more source

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1522-1536, June 2026.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy